Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06982352 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
A Phase 1 study of Atopic Dermatitis (AD) and Psoriasis (PsO), sponsored by LAPIX Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 3
- Study locations
NCT06982352: Recruiting Phase 1 study of Atopic Dermatitis (AD) and Psoriasis (PsO), sponsored by LAPIX Therapeutics.
NCT06982352 is a Phase 1 study of Atopic Dermatitis (AD) and Psoriasis (PsO) that is actively recruiting participants, run by LAPIX Therapeutics. The registered enrollment target is 48 participants, below the 104-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (54% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06982352, a Phase 1 study of Atopic Dermatitis (AD) and Psoriasis (PsO), is actively recruiting participants, sponsored by LAPIX Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.
Primary Outcome
Rate and severity of treatment-emergent adverse events, including serious adverse events.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LPX-TI641
Study Locations (3)
North Dakota
- Red River Research Partners - Fargo
Texas
- Clinical Investigations of Texas - Dallas
Jordan
- Triumpharma Clinical Research Unit at AlEssra Hospital - Amman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-06-15 |
| Est. Completion | 2026-04-15 |
| Phase | Phase 1 |
What NCT06982352 shows while recruiting
NCT06982352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 104-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Atopic Dermatitis (AD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06982352 reports a single indexed study location in North Dakota, Texas, Jordan.
Frequently Asked Questions
What is clinical trial NCT06982352 about?
NCT06982352 is a clinical study titled "Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis". The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI6...
What is the current status of trial NCT06982352?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-06-15. Estimated completion is 2026-04-15.
What conditions does trial NCT06982352 study?
This clinical trial studies the following conditions: Atopic Dermatitis (AD), Psoriasis (PsO).
What interventions are being tested in trial NCT06982352?
The interventions under investigation include: Placebo (DRUG), LPX-TI641 (DRUG).
Who is sponsoring clinical trial NCT06982352?
This trial is sponsored by LAPIX Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06982352 being conducted?
This trial has 3 study locations across North Dakota, Texas, Jordan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis (AD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
RECRUITING · Phase 1
-
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
RECRUITING · Phase 1
-
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
ACTIVE NOT RECRUITING · Phase 1
-
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 1
-
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI